4506 — Sumitomo Pharma Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMid CapNeutral

Annual income statement for Sumitomo Pharma Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Tanshin
Standards:	IFRS	IFRS	IFRS	IFRS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	515,952	560,035	555,544	314,558	398,832
Cost of Revenue
Gross Profit	378,307	402,919	377,050	188,030	245,395
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	444,728	499,801	632,523	669,417	370,028
Operating Profit	71,224	60,234	-76,979	-354,859	28,804
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes	77,851	82,961	-47,920	-323,114	17,611
Provision for Income Taxes
Net Income After Taxes	36,829	40,600	-96,714	-314,929	23,635
Minority Interest
Net Income Before Extraordinary Items
Net Income	56,219	56,413	-74,512	-314,969	23,634
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	56,219	56,413	-74,512	-314,969	23,634
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	164	142	-150	-506	59.5
Dividends per Share